Search in the Abstract Database

Search Abstracts 2013

* = Presenting author

P143. Soluble syndecan-1 (CD138) – a novel biomarker in patients with inflammatory bowel disease

D. Yablecovitch1, A. Stein1,2, T. Naftali1,2, G. Gabay1, I. Laish1, F. Konikoff1,2, 1Meir Medical Center, Gastroenterology, Kfar Saba, Israel, 2Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel

Background

Epithelial barrier dysfunction and impaired mucosal healing have been reported as key factors in the development of inflammatory bowel disease (IBD). Syndecan-1 is a multifunctional extracellular matrix proteoglycan, which mediates basic fibroblast growth factor activity and plays a central role in tissue repair and in maintaining the normal intestinal epithelial barrier. Shedding of syndecan-1 ectodomain from the intestinal epithelium is highly regulated by inflammation. The objective of this pilot study is to determine, for the first time, the concentration of serum soluble syndecan-1 in IBD patients compared to healthy controls.

Methods

A prospective study was performed from January 2012 to October 2012 in our center.

A total of 41 patients with IBD [18 ulcerative colitis (UC), 23 Crohn's disease (CD)] and 16 age and sex matched healthy controls were enrolled. Patients were divided into 3 different groups: active disease – on treatment, active disease – untreated and inactive disease – on treatment. Disease activity was assessed by the Crohn's Disease Activity Index (CDAI), partial Mayo score and C-reactive protein (CRP). Serum concentrations of soluble syndecan-1 were analyzed by ELISA.

Results

IBD patients had significantly higher serum syndecan-1 levels than controls (29.5±13.5 ng/mL vs. 21.2±10.4 ng/mL; p = 0.03). The highest levels of syndecan-1 were found in the active-untreated group (p = 0.006) compared to control. The active-treated group had significantly lower syndecan-1 levels than the active-untreated group (26.8±7.9 ng/mL vs. 38.5±19.4 ng/ml; p = 0.017). No difference in syndecan-1 levels was found between the non active-treated group in comparison to control (26.1±14.7 ng/mL vs. 21.2±10.4 ng/mL; p = 0.34).

Conclusion

Our data show that serum syndecan-1 levels are increased in patients with IBD as compare to healthy controls. The markedly increased syndecan-1 in active-untreated IBD patients may provide an additional tool in assessing disease activity especially in naïve patients. Moreover, these preliminary data suggest that serum syndecan-1 levels are affected by drug treatment. Further investigation of this molecule and its applicability as a biomarker in IBD is warranted.

*The first two authors contributed equally to this study.